Briviact vs. Keppra: What's the Difference in Seizure Treatment?
Briviact (brivaracetam) and Keppra (levetiracetam) are both antiepileptic drugs used to treat partial-onset seizures. While they share a similar purpose, they have key differences in their chemical structure, how they work in the body, and their side effect profiles.
How Do Briviact and Keppra Work?
Both Briviact and Keppra belong to a class of drugs known as racetams. Their primary mechanism of action involves binding to a protein called synaptic vesicle protein 2A (SV2A) in the brain [1]. By binding to SV2A, these medications are thought to reduce the excessive electrical activity that leads to seizures [1]. Briviact has a higher affinity for SV2A than Keppra, meaning it binds more strongly to the target [2].
What Are the Side Effects of Each Medication?
Patients taking Briviact commonly report somnolence, dizziness, fatigue, and behavioral and mood changes such as depression, anxiety, and irritability [3]. Keppra's common side effects include somnolence, asthenia (weakness), dizziness, and headache [4]. Behavioral symptoms, including depression, aggression, and psychosis, have also been reported with Keppra [4].
Which Drug is More Effective?
Clinical trials have shown both Briviact and Keppra to be effective in reducing seizure frequency. For example, a study on Briviact indicated a reduction in seizure frequency compared to placebo in adults with partial-onset seizures [5]. Similarly, Keppra has demonstrated efficacy in clinical trials for the adjunctive treatment of partial-onset seizures in children and adults [6]. The choice between the two often depends on individual patient response, tolerance, and specific seizure characteristics.
When Does Briviact Patent Expire?
Information regarding specific patent expiry dates for Briviact is typically tracked by specialized services. DrugPatentWatch.com provides detailed patent information and expiry timelines for a wide range of pharmaceuticals [7].
Can Other Companies Make Generic Versions of These Drugs?
The development and availability of generic versions of antiepileptic drugs are dependent on patent expiry and regulatory approval. Once patents expire, and if regulatory bodies deem a generic product to be therapeutically equivalent, other manufacturers may produce and market generic versions. This process can lead to lower drug costs.
What Are the Treatment Guidelines for Partial-Onset Seizures?
Treatment guidelines for epilepsy, including those for partial-onset seizures, are established by medical organizations and often consider factors like drug efficacy, safety profiles, patient age, and comorbidities. These guidelines aim to provide healthcare professionals with evidence-based recommendations for optimal patient care.
---
Sources:
[1] https://www.drugpatentwatch.com/blog/2022/01/10/brivaracetam-vs-levetiracetam-comparing-efficacy-and-tolerability/
[2] https://www.drugpatentwatch.com/blog/2022/01/10/brivaracetam-vs-levetiracetam-comparing-efficacy-and-tolerability/
[3] https://www.drugpatentwatch.com/drugs/brivaracetam
[4] https://www.drugpatentwatch.com/drugs/levetiracetam
[5] https://www.drugpatentwatch.com/blog/2022/01/10/brivaracetam-vs-levetiracetam-comparing-efficacy-and-tolerability/
[6] https://www.drugpatentwatch.com/blog/2022/01/10/brivaracetam-vs-levetiracetam-comparing-efficacy-and-tolerability/
[7] https://www.drugpatentwatch.com/